GGT1 and benign prostatic hyperplasia: Moreover, Survivin [148] and GGT1 [149] showed higher serum sEV activity in PCa patients compared to BPH patients, suggesting that serum sEV Survivin/GGT activity may serve as a potential biomarker for PCa.